NDPS Supply Chain Compliance: What the June 2026 Enforcement Wave Means for Pharma

Enforcement Has Intensified — And Manufacturers Are in the Crosshairs

India’s narcotics enforcement landscape shifted dramatically in the first half of 2026. What began as isolated state-level raids has escalated into a coordinated, nationwide crackdown on diverted pharmaceutical narcotics. On 20 June 2026, law enforcement agencies and drug control departments across multiple Indian states simultaneously intensified operations targeting the illegal trade of narcotic and habit-forming drugs, with major seizures reported within days of each other. These were not isolated incidents — they signal a systemic tightening of oversight that reaches directly back to licensed pharmaceutical manufacturers.

For compliance officers and regulatory teams at pharma companies, the message is clear: supply chain documentation failures at the manufacturer level are now an enforcement trigger, not merely a paperwork lapse.

The DCC’s Real-Time Tracking Portal: What Pharma Companies Must Prepare For

The most consequential structural development of 2026 is the formal approval — by India’s Drugs Consultative Committee (DCC) — of a centralised, real-time digital portal for end-to-end tracking of all pharmaceutical products regulated under the Narcotic Drugs and Psychotropic Substances Act, 1985. At a meeting reported on 9 April 2026, the DCC heard the case for an end-to-end mechanism for tracking medicine production, imports, exports, sales, distribution, and stock. The DCC approved the proposal and recommended that CDSCO meet with the Central Bureau of Narcotics (CBN) to discuss the planned portal’s implementation.

The portal’s scope will cover products regulated under the NDPS Act, 1985, and will involve both CDSCO and state drug regulatory authorities in its operational framework. The DCC deliberated on regulatory and legal considerations, the implementation strategy, and the functional features of the system. While a go-live date has not yet been formally gazetted, the approval marks the point of no return — pharmaceutical manufacturers producing or trading in narcotic drugs, psychotropic substances, and Schedule H/H1 formulations should begin aligning internal systems now.

What the Portal Will Demand From Manufacturers

• Real-time inventory reporting: Production, import, export, sales, and distribution data will need to be captured and reported in near real-time — not monthly, as currently required.
• Granular stock visibility: Manufacturers will need batch-level traceability for narcotic and psychotropic formulations throughout the supply chain.
• Integration with CDSCO and CBN systems: Companies already operating on SUGAM and cbnonline.gov.in should anticipate a convergence of reporting streams.
• Documentation readiness: The portal will make documentation gaps visible to regulators instantly — companies without robust internal SOPs will face immediate exposure.

The June–July 2026 Enforcement Wave: Key Seizures and the Manufacturer Liability Question

The enforcement data from June 2026 is striking in its geographic spread and the categories of products involved. Multiple police operations across Indian states uncovered thousands of Diazepam injections, Tramadol capsules, Pregabalin, and codeine-based cough syrups in just four days around 13 June 2026. On 29 June 2026, a joint raid in Uttar Pradesh’s Bahraich district resulted in the seizure of over 2,349 bottles of codeine-laced cough syrup of eight varieties (weighing approximately 235 kg) and 12,145 Tramadol capsules — all traceable to a licensed supply network operating without valid documentation at the point of storage.

The enforcement pattern is consistent with findings from earlier in 2026. As of April 16, 2026, enforcement agencies across at least seven Indian states reported major seizures of prescription drugs being illegally traded. In March 2026, police raids specifically called out codeine-based cough syrups and psychotropic tablets as primary targets. In every case, the contraband was traced upstream — and the question of manufacturer liability for downstream diversion is now actively being litigated.

The Supreme Court Tramadol Ruling: A Warning for Pharma Supply Chains

In Dr. Rajinder Rajan vs. Union of India & Anr (SLP(Crl.) No. 3326 of 2026), the Supreme Court granted bail to medical professionals arrested after the Narcotics Control Bureau conducted a raid at a pharmaceutical company and recovered 31,900 Tramadol tablets. The case arose when a pharmaceutical company made a supply error — shipping 2,000 tablets instead of 200 — and before the excess could be returned, the NCB raided the company’s premises. The Court’s bail order hinged on a procedural point regarding written grounds of arrest, but the underlying facts expose a stark reality: even a documented supply error, before it can be rectified, can trigger an NCB raid, an FIR, and arrests across the supply chain.

For manufacturers, the lesson is not subtle. Every supply transaction involving Tramadol, codeine, Tapentadol, Nitrazepam, Buprenorphine, Pregabalin, and other NDPS-regulated formulations must be supported by complete purchase orders, delivery challans, valid licences for the recipient, and return-to-stock documentation — maintained contemporaneously, not reconstructed after the fact.

Codeine Preparations: The Dual-Act Trap That Continues to Catch Manufacturers

A persistent misconception in the industry is that codeine-based cough syrup manufacturers are fully insulated from NDPS liability because their products are regulated under the Drugs and Cosmetics Act, 1940. Courts have consistently rejected this argument. The exemption under Notification S.O. 826(E) dated 14 November 1985 — which excludes certain codeine preparations from the definition of “manufactured drugs” — applies only when specific cumulative conditions are met, including prescribed concentration limits, compounding with other therapeutic ingredients, and establishment in therapeutic practice.

Critically, courts have held that failure to meet even one of these conditions revives the prohibition under Section 8 of the NDPS Act, and the burden of establishing entitlement to the exemption lies squarely on the accused. The Allahabad High Court has declined to quash NDPS proceedings in cases involving large-scale stocking or unexplained transport of codeine-based medicines — even where the manufacturer held a valid Drugs and Cosmetics Act licence. Manufacturers must audit every codeine preparation in their portfolio against these exemption criteria, and ensure that each distributor in the downstream chain holds the correct licence and documentation for the category.

Practical Compliance Checklist for Pharmaceutical Manufacturers: July 2026

Supply Chain Documentation

• Maintain complete batch-level records for all narcotic and psychotropic formulations — purchase bills, delivery challans, recipient licence copies, and written requisitions — at every handoff point.
• Verify that every distributor and stockist in your narcotic supply chain holds a valid licence specifically covering the NDPS-scheduled products you supply to them.
• Establish a contemporaneous return-to-stock documentation protocol for supply errors involving NDPS-regulated drugs — do not rely on informal communications.
• Audit distribution agreements to confirm that downstream sale obligations, geographic restrictions, and documentation requirements are contractually bound and monitored.

CBN Compliance Obligations (Ongoing)

• File monthly returns by the 7th of each month via cbnonline.gov.in — missed returns directly jeopardise future export authorisations and quota allocations.
• Ensure your CBN Registration Certificate (CRC) under Rule 65 is current and reflects accurate company details.
• Exporters must submit shipping bills and invoices to both the Narcotics Commissioner and the DCGI under the updated Form 5 export authorisation workflow introduced by the December 2025 amendment rules.
• Update internal SOPs to incorporate new Form 4A fields (HSN Code, CAS number, GSTIN) before the next import application cycle — and track the 180-day completion window on all active import certificates.

Preparing for the DCC Digital Portal

• Conduct an internal systems audit: map every data point currently captured in your ERP or inventory management system against the likely portal requirements (batch number, quantity, recipient, dispatch date, licence number).
• If your company does not yet use SUGAM or cbnonline.gov.in for all applicable filings, transition now — the portal is expected to interface with existing CBN and CDSCO digital infrastructure.
• Engage your IT and compliance teams to build automated reporting workflows for NDPS-regulated SKUs so that portal compliance is not a manual, error-prone exercise.

Legal Exposure Management

• Train your regulatory and distribution teams on the dual-applicability of the NDPS Act and the Drugs and Cosmetics Act — a valid D&C Act licence does not shield a manufacturer from NDPS prosecution where the facts support a diversion finding.
• Ensure all codeine preparations are audited against the S.O. 826(E) exemption criteria — concentration, compounding, and therapeutic practice requirements must all be satisfied simultaneously.
• Review your Schedule H1 documentation practices in light of the ongoing judicial scrutiny; the standard for “complete documentation at each handoff point” is being set by High Court and Supreme Court decisions in live 2026 cases.

The Bottom Line

The DCC’s approval of the real-time NDPS tracking portal, combined with a nationwide enforcement wave that has not abated through June and into July 2026, marks a structural shift in how narcotic drug compliance is regulated in India. The era of reactive compliance — maintaining records but not actively monitoring the chain — is ending. Manufacturers who have not yet built proactive, batch-level, end-to-end documentation systems for their NDPS-regulated products should treat this as a priority action item, not a future-quarter project.

ACPL’s regulatory experts can help you navigate NDPS Act and narcotics supply chain compliance for your pharmaceutical business. Contact us at info@acplgroupindia.co.in or call +91-9266665201 for a consultation.